Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said
You may also be interested in...
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
Korea Trade Commission Launches Kickback Probes Of Pharmaceutical Firms Following Similar Action By Drug Regulators
SEOUL - To underscore the government's crackdown on kickbacks ahead of the implementation of a new law on the topic slated to become effective in late November, South Korea's Fair Trade Commission is launching probes of several Korean pharmaceutical firms suspected of providing illicit payments to hospitals and doctors